Twist Bioscience Earnings Call Transcripts
Fiscal Year 2026
-
Strong growth driven by new product launches, automation, and AI-enabled services has expanded the addressable market and improved margins. Strategic focus on high-throughput solutions, commercial excellence, and a shift to fee-for-service contracts positions the company for continued revenue and margin expansion.
-
Resegmentation and AI integration are driving rapid growth in DNA synthesis, protein solutions, and NGS, with new products like TrueAmp and MRD Express expanding market reach. Margin expansion continues, supported by operational scale and innovation, with breakeven targeted by Q4.
-
Management reaffirmed the goal of Adjusted EBITDA breakeven by Q4 FY2026, driven by margin expansion and disciplined OpEx. AI and MRD are fueling rapid growth, with automation and product innovation providing competitive advantages. Long-term, the addressable market is targeted to reach $12B+.
-
The meeting covered board introductions, voting on three key proposals, and a Q&A session. All director nominees were elected, executive compensation was approved, and the auditor was ratified. No questions were submitted by stockholders.
-
Q1 revenue grew 17% year-over-year to $103.7M, with gross margin rising to 52% and strong demand from AI-driven discovery. Guidance for FY26 was raised to $435M–$440M, with adjusted EBITDA break-even expected in Q4. Investments in sales and digital infrastructure support continued growth.
-
Semiconductor-based DNA synthesis technology and rapid product innovation have driven strong revenue growth, margin expansion, and customer acquisition. AI-enabled drug discovery and NGS applications are key growth drivers, with break-even targeted for Q4 2026.
Fiscal Year 2025
-
Revenue and gross margin exceeded guidance despite a tough environment, with strong growth in both NGS and DNA synthesis segments. A major pharma order and new product wins are driving momentum, while a single NGS customer transition is causing short-term revenue noise. New disclosures and a focus on revenue growth are expected to support future upside.
-
Record Q4 and full-year revenue growth, with gross margin surpassing 50% and significant improvements in adjusted EBITDA loss. Fiscal 2026 guidance projects 13–15.5% revenue growth, margin expansion, and adjusted EBITDA breakeven by year-end, driven by AI and diagnostic customer ramps.
-
The business is leveraging its miniaturized DNA synthesis platform to drive growth across SynBio, NGS, and Biopharma, with strong revenue and margin expansion. Key opportunities include MRD in NGS and AI-driven drug discovery, while maintaining innovation and culture are top priorities.
-
Q3 revenue grew 18% year-over-year to $96.1 million, with gross margin exceeding 53% and strong performance across SynBio, NGS, and biopharma segments. FY25 guidance was raised, and the company is on track for Adjusted EBITDA break-even by Q4 2026.
-
The presentation highlighted robust revenue growth, margin expansion, and strong cash reserves, driven by innovative DNA synthesis technology and a scalable, automated platform. Product diversification and operational excellence support continued market share gains in SynBio, NGS, and biopharma, with significant opportunities in emerging markets and academic segments.
-
Q2 delivered record revenue and margin growth, driven by strong Synbio, NGS, and biopharma performance. The Atlas Data Storage spinout strengthens focus and finances, while guidance for FY25 and FY26 remains robust despite macro uncertainties.
-
Express Genes was launched for academics at zero premium to accelerate share gains, with strong adoption seen across all segments. Operational improvements and automation are driving margin expansion, while new NGS tools and menu expansion support long-term growth. US manufacturing and supply chain security are emerging as competitive advantages.
-
A temporary zero-premium offer for academic customers and dynamic pricing are driving market share gains, supported by robust process improvements and facility expansion. Gross margin is up to 48% with a target of 50%+, and disciplined OpEx is accelerating the path to profitability.
-
Consistent revenue growth, expanding gross margins, and flat OPEX are driving profitability, supported by automation and innovation. AI integration and new product launches in NGS and mRNA are fueling growth, while a diversified customer base and in-house technology provide resilience and competitive advantage.
-
Record revenue and gross margin growth driven by SynBio and NGS, with improved profitability and raised FY25 guidance. Cost-saving initiatives and U.S.-based manufacturing provide competitive advantages, while diversified customer base and innovation support resilience in a challenging market.
-
Silicon chip-based synthesis and automation drive innovation and cost efficiency, supporting strong revenue growth and margin expansion. New product launches, operational discipline, and U.S.-based manufacturing position the company for profitable growth, with a focus on reaching Adjusted EBITDA breakeven and expanding into data storage.
Fiscal Year 2024
-
Revenue and gross margin growth are driven by differentiated products, commercial velocity, and expanding capacity. New product launches and U.S.-based manufacturing strengthen competitive positioning, while sequential improvements in orders and revenue are expected to continue into 2025.
-
Record Q4 and FY 2024 revenue and margin growth, with strong performance in SynBio, NGS, and biopharma. FY 2025 guidance projects 17%-20% revenue growth and continued margin expansion, with a focus on reaching Adjusted EBITDA breakeven and cash flow positivity.
-
Silicon chip technology and new product launches have driven revenue growth, margin improvement, and customer expansion, especially in SynBio and NGS. Process improvements have boosted manufacturing capacity, while profitability remains a key focus for the coming years.
-
Q3 FY24 revenue grew 28% year-over-year to $81.5 million, with gross margin up to 43.3%. SynBio and NGS segments drove growth, while a $45 million biopharma impairment was recorded. FY24 revenue guidance was raised, and the company remains focused on margin improvement and profitability.
-
Miniaturized DNA synthesis and Express Genes drive growth, margin expansion, and market share gains, supported by strong IP, software, and supply chain advantages. New product launches and disciplined R&D leverage the silicon platform, while flexible capacity and blanket orders enhance revenue visibility.
-
Significant revenue growth and margin expansion are driven by proprietary silicon chip technology, enabling scalable production and innovative products across SynBio, NGS, Biopharma, and emerging DNA data storage. Speed, cost, and sustainability advantages support strong market positioning.
-
Management outlined a strategy focused on scalable growth, margin expansion, and innovation across DNA synthesis, NGS, biopharma, and data storage. Guidance projects continued revenue and margin growth, with a clear path to profitability and no need for additional capital.